RxDoctor Payments Data

Sanjeev Goyal, MD

Clinical Cardiac Electrophysiology · Worcester, MANPI 1629044102

Payments from drug & device makers

$6,707in general payments, 2019–2025

Across 90 payments — averaging $74.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Pfizer$525
  • Boehringer Ingelheim$262
  • Novartis$254
  • Actelion Pharmaceuticals US, Inc.$129
  • plus $326 from 7 others

What the payments were for

  • Consulting fees$45012%
  • Travel & lodging$1,47439%
  • Food & beverage$1,74347%
  • Education$802%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,707 in reported general payments places this provider in the 30th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$352,854
Medicare patients
455
Services billed
3,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis32$1,094,808
EliquisApixaban305$377,378
JardianceEmpagliflozin178$233,024
XareltoRivaroxaban74$107,622
EntrestoSacubitril/Valsartan55$79,887
CorlanorIvabradine Hcl22$31,070
Repatha SyringeEvolocumab18$18,694
FarxigaDapagliflozin Propanediol11$18,266
Dofetilide43$14,900
Metoprolol Succinate705$13,667
Flecainide Acetate254$12,252
Dabigatran EtexilateDabigatran Etexilate Mesylate20$5,263
Colchicine19$5,142
Losartan Potassium275$2,660
Rosuvastatin Calcium74$2,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$525$1,472,186337 claims
Boehringer IngelheimJardiance$262$233,024178 claims
Johnson & JohnsonXarelto$14$107,62274 claims
NovartisEntresto$254$79,88755 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →